A chemosensitive small round cell sarcoma that happens to make cartilage — never manage it like a conventional chondrosarcoma
- Biphasic histology: sheets of primitive small round blue cells with a haemangiopericytoma-like branching vascular pattern, abruptly transitioning to islands of well-differentiated hyaline cartilage.
- HEY1-NCOA2 fusion is the diagnostic molecular hallmark, detected by RT-PCR or fusion-directed next-generation sequencing; it is not present in conventional chondrosarcoma or Ewing sarcoma.
- Unlike conventional chondrosarcoma (chemoresistant and radioresistant), mesenchymal chondrosarcoma is chemosensitive — surgery alone is inadequate treatment.
- Craniofacial bones, ribs, spine, pelvis and femur are the classic sites; a jaw or rib lesion in a 20-year-old with stippled calcification should raise it.
- A small biopsy sampling only the small cell area is readily misdiagnosed as Ewing sarcoma, synovial sarcoma, small cell osteosarcoma or solitary fibrous tumour.
- Late relapse beyond 10 years is characteristic; surveillance must be lifelong, not five-year.
- “Radiologically it is an aggressive lytic destructive lesion with a soft-tissue mass containing stippled or ring-and-arc chondroid calcification — the mix of aggression and chondroid matrix is the clue.
- “Immunohistochemistry: small cells are CD99 positive (a trap), SOX9 positive, and the cartilage islands are S100 positive; NKX2.2 and FLI1 help exclude Ewing sarcoma.
- “Grading is not applied — all mesenchymal chondrosarcoma is treated as high grade regardless of how mature the cartilage looks.
- “Discordance between a benign-looking cartilage island on frozen section and a clinically aggressive lesion should never downgrade the plan.
- “Local recurrence and pulmonary metastasis dominate failure; margin quality remains the strongest surgeon-controlled variable.
Conventional chondrosarcoma is managed by surgery alone. Mesenchymal chondrosarcoma requires wide resection PLUS multi-agent chemotherapy. Omitting systemic therapy because the pathology report says "chondrosarcoma" is a career-defining error — read the qualifier.
The small cell component is frequently CD99 membranous positive. Combined with a small round blue cell morphology on a needle core, this produces a false diagnosis of Ewing sarcoma. Demand molecular testing: HEY1-NCOA2 versus EWSR1 rearrangement.
A core through the cartilage island alone reads as low-grade cartilage tumour; a core through the small cell area alone reads as round cell sarcoma. Plan an image-guided multi-site biopsy through the enhancing soft-tissue mass, tract placed for later excision, at the treating sarcoma unit.
Relapse at 10, 15 and even 20 years is well documented. Discharging at five years is unsafe. Sustained chest and local imaging surveillance, with clear handover to the patient and primary physician, is part of the operation's aftercare.
Definition, Epidemiology and Biology
Mesenchymal chondrosarcoma is a rare high-grade malignant cartilage-forming tumour defined by a biphasic architecture of undifferentiated small round cells and islands of well-formed hyaline cartilage. It is biologically closer to the translocation-associated round cell sarcomas than to the enchondroma–chondrosarcoma continuum, and its clinical behaviour and treatment follow that biology.
Epidemiology
- Accounts for approximately 1 to 2 percent of chondrosarcomas; a genuinely rare tumour with worldwide incidence in the range of a few cases per ten million per year.
- Peak incidence in the second and third decades, i.e. a decade or two earlier than conventional chondrosarcoma. Cases occur from childhood to the sixth decade.
- Slight female predominance in most series; no established geographic or ethnic clustering.
- Skeletal sites (roughly two thirds): craniofacial bones (maxilla, mandible, skull base), ribs, vertebrae, ilium and other pelvic bones, femur and humerus. Craniofacial and axial predilection is a strong distinguishing feature from conventional chondrosarcoma.
- Extraskeletal (roughly one third): meninges and brain, orbit, head and neck soft tissue, lower limb musculature, retroperitoneum.
Molecular pathology
- The recurrent HEY1-NCOA2 fusion (an intrachromosomal deletion on 8q) is present in the great majority of cases and is the diagnostic molecular hallmark.
- A minority harbour IRF2BP2-CDX1.
- Neither fusion is found in conventional or dedifferentiated chondrosarcoma, Ewing sarcoma, or small cell osteosarcoma — hence its discriminating value.
- IDH1/IDH2 mutations, characteristic of conventional central chondrosarcoma, are absent, which is another useful negative discriminator.
Staging and Multidisciplinary Planning
Suspected primary bone sarcoma referred before biopsy to a sarcoma centre. Local radiograph, whole-bone MRI with contrast, CT of the lesion, staging chest CT, bloods including LDH and alkaline phosphatase.
Image-guided core biopsy with tract planning; fresh tissue for RNA-based fusion testing. Whole-body staging (PET-CT or bone scintigraphy).
Radiologist, sarcoma pathologist, medical and radiation oncologist, orthopaedic and, where relevant, maxillofacial, neurosurgical or thoracic surgeon. Decide resectability, reconstruction, and whether radiotherapy is required. Fertility preservation counselling before chemotherapy in this young population.
Multi-agent regimen; baseline echocardiogram and audiometry as dictated by agents used. Restaging MRI and chest CT before surgery.
Definitive local control with reconstruction. Margins assessed by the pathologist on the intact specimen.
Completion of chemotherapy once the wound is sound; radiotherapy for close, marginal or intralesional margins or unresectable disease. Surveillance protocol initiated and explicitly stated to be lifelong.
Staging uses the standard bone sarcoma frameworks — the Enneking (MSTS) system (all mesenchymal chondrosarcoma is high grade, therefore stage IIA if intracompartmental, IIB if extracompartmental, III if metastatic) and the AJCC system. Grading of the cartilage component is not performed and must never be used to argue for de-escalation.
Clinical Presentation and Examination
- Pain and progressive swelling over weeks to months are the dominant symptoms; night pain and rest pain suggest a malignant process.
- Craniofacial disease: facial swelling, loosening teeth, malocclusion, nasal obstruction, epistaxis, proptosis or diplopia (orbital or skull base extension), cranial nerve palsies.
- Rib and chest wall: chest wall mass, pleuritic pain, occasionally an incidental finding on a chest radiograph obtained for another reason.
- Spine: axial pain progressing to radicular pain, then myelopathy or cauda equina symptoms — a fast tempo of neurological decline is characteristic of an aggressive extradural mass.
- Pelvis: deep dull pain, referred to the groin or buttock, often mistaken for hip pathology; large tumour volume before diagnosis because the pelvis accommodates growth silently.
- Ask specifically about duration, tempo of change, prior irradiation, constitutional symptoms and family history of syndromic cancer.
Imaging: What to Order and How to Read It
Plain radiograph (two orthogonal views, whole bone).
- Aggressive lytic destruction with a wide zone of transition and ill-defined margins (Lodwick grade III behaviour).
- Stippled, flocculent, punctate or ring-and-arc calcification within the lesion or the associated soft-tissue mass — the chondroid signature.
- Cortical destruction and an extraosseous soft-tissue mass; periosteal reaction is variable and may be interrupted.
- In the mandible or maxilla, a lytic destructive lesion with root resorption and a soft-tissue component.
CT (with intravenous contrast; the matrix study).
- Best modality for matrix characterisation — the punctate and ring-and-arc calcification that separates a chondroid tumour from Ewing sarcoma or lymphoma.
- Defines cortical breach, endosteal scalloping, pathological fracture risk and, in the pelvis or skull base, the exact osseous corridors for resection.
- Staging chest CT is mandatory at diagnosis: the lung is the dominant metastatic site and small nodules will be missed on radiograph.
- CT angiography where the mass abuts iliac, femoral, subclavian or vertebral vessels, to plan vascular control or reconstruction.
Biopsy: Principles and the Classic Pitfall
An unplanned or badly sited biopsy contaminates compartments, converts a limb-sparing resection into an amputation, and complicates flap reconstruction. Referral before biopsy is the standard of care worldwide for any suspected primary bone sarcoma.
Technique.
- Image-guided core needle biopsy (CT for deep osseous or pelvic lesions, ultrasound for a soft-tissue component) is first line; open incisional biopsy is reserved for non-diagnostic cores.
- Target the enhancing solid soft-tissue component identified on post-contrast MRI or the PET-avid region — avoid necrotic centre and avoid sampling only the mineralised cartilage island.
- Take multiple cores from more than one region of the mass to capture both phases. Send fresh tissue for molecular studies as well as formalin-fixed material.
- Longitudinal tract in line with the planned incision, shortest route through one compartment, no transgression of neurovascular bundles or an uninvolved joint. Mark the skin entry point with an indelible ink dot or a small tattoo and document it — the tract is excised en bloc.
- Achieve meticulous haemostasis; a haematoma disseminates tumour along fascial planes.
Histopathology.
- Biphasic pattern: sheets and nests of primitive small round to spindled cells with scant cytoplasm and a haemangiopericytoma-like (staghorn) branching vascular pattern, abruptly interrupted by islands of well-differentiated hyaline cartilage that may show endochondral ossification.
- Mitoses are present in the small cell component; necrosis is common.
- Immunohistochemistry: small cells CD99 positive (membranous, frequently), SOX9 positive, desmin negative; cartilage islands S100 and SOX9 positive. NKX2.2 is typically negative (contrast Ewing sarcoma, which is NKX2.2 positive). STAT6 is negative (excludes solitary fibrous tumour). TLE1 may be weakly positive and must not be over-read as synovial sarcoma.
- Molecular confirmation: RT-PCR or targeted RNA sequencing for HEY1-NCOA2; EWSR1 and SS18 rearrangements absent.
A core biopsy that samples only the primitive small cell region reads as a small round blue cell tumour, CD99 positive — and is reported as Ewing sarcoma. The cartilage islands may be entirely absent from a 1 mm core. If a "Ewing sarcoma" arises in the mandible, rib or skull base of a young adult and the imaging shows chondroid stippling, insist on molecular testing before committing to a Ewing protocol.
BIPHASICRecognising Mesenchymal Chondrosarcoma
Hook:Two faces, one tumour — and it needs two treatments: the knife and the drip.
Treatment Principles
- Conventional chondrosarcoma
- 5th to 7th decade
- Mesenchymal chondrosarcoma
- 2nd to 3rd decade
- Conventional chondrosarcoma
- Pelvis, proximal femur, proximal humerus
- Mesenchymal chondrosarcoma
- Craniofacial, ribs, spine, pelvis; one third extraskeletal
- Conventional chondrosarcoma
- IDH1 or IDH2 mutation frequent
- Mesenchymal chondrosarcoma
- HEY1-NCOA2 fusion; IDH wild type
- Conventional chondrosarcoma
- Not indicated — chemoresistant
- Mesenchymal chondrosarcoma
- Indicated — multi-agent regimens improve survival in reported series
- Conventional chondrosarcoma
- Relatively radioresistant; particle therapy for unresectable skull base
- Mesenchymal chondrosarcoma
- Useful adjuvant for close margins and unresectable axial disease
- Conventional chondrosarcoma
- Wide resection alone
- Mesenchymal chondrosarcoma
- Wide resection as part of multimodal therapy
- Conventional chondrosarcoma
- Local recurrence, late lung metastasis
- Mesenchymal chondrosarcoma
- Local recurrence and lung metastasis, characteristically very late
Decision thresholds
- Resectable disease, no metastases: neoadjuvant multi-agent chemotherapy, then wide en bloc resection, then adjuvant chemotherapy. This is the standard pathway in contemporary sarcoma practice.
- Margin achievable but predicted close (spine, pelvis, skull base): add adjuvant radiotherapy; consider proton or carbon ion therapy at the skull base and mobile spine where dose to cord and optic apparatus limits photons.
- Unresectable disease: chemotherapy plus definitive high-dose radiotherapy; reassess resectability after response.
- Pathological fracture or impending fracture: stabilise the biology first where possible; definitive resection remains the aim, and internal fixation through an unresected sarcoma contaminates the whole bone and is a reconstructive disaster.
- Metastatic at presentation: systemic therapy first. In good responders with limited pulmonary disease, metastasectomy plus primary resection offers meaningful long-term survival and is worth pursuing.
- Local recurrence: re-resection where feasible; recurrence is a strong adverse prognostic marker and should trigger re-staging and multidisciplinary re-planning rather than a reflex further local procedure.
The primitive small round cell component behaves like other translocation-driven round cell sarcomas and responds to anthracycline and alkylating agent based regimens. Registry and multi-institutional series consistently report better survival in chemotherapy-treated patients, particularly those with localised disease and those undergoing complete resection. The cartilage islands themselves are not chemosensitive — which is why systemic therapy never replaces the operation.
Surgery: Wide En Bloc Resection
Indication. Localised or oligometastatic mesenchymal chondrosarcoma where a wide margin is achievable with acceptable function.
Contraindications. Unreconstructable vital structure involvement (e.g. circumferential encasement of brainstem, bilateral carotid, or aorta), widely disseminated disease without response to systemic therapy, or a patient unfit for major resection. Relative: an anatomical site where wide margin would demand unacceptable neurological sacrifice — here plan planned close margin plus radiotherapy.
Why this operation over alternatives. Intralesional curettage, adequate for low-grade central cartilage tumours of the appendicular skeleton, is never acceptable here: the small cell component is high grade and seeds locally. Radiotherapy alone gives inferior local control where resection is feasible.
PIPADRAW sequence (worked for an iliac wing or periacetabular resection, the commonest orthopaedic scenario):
- Position: floppy lateral or supine on a radiolucent table with a bump; prepare the whole hemipelvis, ipsilateral limb free-draped to allow intraoperative manipulation, abdomen prepared to the costal margin. Urinary catheter; consider preoperative ureteric stents for large pelvic masses.
- Imaging and equipment: image intensifier, navigation or patient-specific instrumentation where available for the osteotomy planes, cell salvage not used, vascular clamps and grafts available, oscillating and Gigli saws, high-speed burr, allograft or endoprosthetic implants on the shelf, plastic surgery and vascular surgery on standby.
- Preparation: cross-matched blood, tranexamic acid, antibiotic prophylaxis, normothermia, considered preoperative embolisation of a hypervascular mass, marking of the biopsy tract with an ellipse of skin.
- Approach: ilioinguinal or utilitarian pelvic approach tailored to the tumour; incision incorporates the biopsy tract ellipse.
- Dissection: stay outside the reactive zone at all times — dissect through normal tissue planes, taking a cuff of muscle over the tumour. Ligate and divide internal iliac branches as required. Never enter the pseudocapsule.
- Reduction/Resection/Reconstruction: perform planned osteotomies with a margin measured from preoperative MRI (aim for at least 1 to 2 cm of bone beyond marrow signal abnormality, adjusted for anatomical constraint). Deliver the specimen intact and orient it for the pathologist with sutures and a diagram. Reconstruct according to zone — Enneking zone I resections often need no reconstruction; periacetabular (zone II) resections require pelvic endoprosthesis, allograft-prosthetic composite, hip transposition or ischiofemoral arthrodesis depending on resource and surgeon preference.
- At-risk structures: external and internal iliac vessels, femoral and obturator nerves, lumbosacral trunk and sciatic nerve, ureter, bladder, rectum and superior gluteal vessels (their sacrifice compromises flap viability).
- Fixation: implants placed only after the tumour is out and instruments changed; separate clean set.
- Closure: meticulous dead space obliteration with muscle flaps, drains brought out in line with the incision so the tract can be included in any future re-resection, layered tension-free closure.
- Aftercare: thromboprophylaxis, protected weight bearing dictated by reconstruction, early physiotherapy, chemotherapy resumed once the wound is healed (commonly at 2 to 3 weeks).
- Pitfalls: tumour spillage, unrecognised skip lesion, biopsy tract not excised, drain sited remotely, resuming chemotherapy over a compromised wound.
- Salvage of failure: re-resection for positive margin where anatomically possible; otherwise adjuvant radiotherapy. Deep infection of a megaprosthesis is managed by debridement with component retention early, or two-stage revision or amputation late.
Prognosis and Surveillance
- Reported 5-year overall survival is typically in the 50 to 60 percent range in multimodal series; 10-year survival falls substantially, reflecting late relapse.
- Favourable factors: localised disease at presentation, complete resection with negative margins, extraskeletal or appendicular location amenable to wide excision, receipt of chemotherapy, smaller tumour volume, good histological response to neoadjuvant therapy.
- Adverse factors: metastatic disease at diagnosis, axial or skull base site, positive margin, local recurrence, large tumour size.
- Failure pattern: local recurrence and pulmonary metastasis, with bone and lymph node metastasis less common. Relapse at 10 to 20 years is well documented and is the single most distinctive prognostic feature of this tumour.
Surveillance schedule (pragmatic, adapted to resources):
- Clinical
- Examination of site and regional nodes
- Local imaging
- MRI or CT of operative site
- Chest imaging
- CT chest
- Clinical
- Examination plus function assessment
- Local imaging
- MRI or CT of site
- Chest imaging
- CT chest, radiograph alternating where CT access limited
- Clinical
- Examination, implant review
- Local imaging
- Site imaging annually
- Chest imaging
- Chest imaging annually
- Clinical
- Annual review; survivorship, cardiac and endocrine late effects
- Local imaging
- Site imaging for new symptoms plus periodic
- Chest imaging
- Annual chest imaging
Counsel the patient explicitly that this tumour can return more than a decade later, and that new chest symptoms, local swelling or pain must trigger immediate review. Hand over a written surveillance plan to the patient and their primary care physician — essential where patients relocate across borders or health systems.
Guidelines, Registries & Global Practice
Global epidemiology and access. Mesenchymal chondrosarcoma is uniformly rare across all populations with no established geographic clustering. The dominant global variable is access to a sarcoma centre, molecular diagnostics and multi-agent chemotherapy. In many low- and middle-income settings, fusion testing is unavailable and diagnosis rests on morphology and immunohistochemistry alone — an acceptable pragmatic pathway provided the biphasic pattern is recognised and CD99 positivity is not over-interpreted. Telepathology and regional reference laboratories are increasingly used to bridge this gap.
Society guidance that genuinely addresses this tumour:
- Relevant guidance
- Bone sarcomas should be diagnosed and treated in reference centres or networks; mesenchymal chondrosarcoma is treated with chemotherapy in addition to surgery, unlike conventional chondrosarcoma
- Practical consequence
- Refer before biopsy; do not extrapolate conventional chondrosarcoma management
- Relevant guidance
- Recognises mesenchymal chondrosarcoma as a distinct chemosensitive subtype; recommends wide excision plus consideration of chemotherapy and radiotherapy
- Practical consequence
- Supports neoadjuvant and adjuvant systemic therapy in localised disease
- Relevant guidance
- Centralised sarcoma diagnostic and treatment services with mandatory multidisciplinary team review and defined referral pathways
- Practical consequence
- Structural argument for centralisation applicable to any health system
- Relevant guidance
- Any suspected primary bone tumour should be referred to a specialist centre before biopsy
- Practical consequence
- Prevents the unplanned-biopsy disaster that most commonly harms these patients
- Relevant guidance
- Defines mesenchymal chondrosarcoma as a distinct entity with HEY1-NCOA2 fusion; no grading applied
- Practical consequence
- All cases are high grade; grading language should not appear in the report
Registry evidence. There is no implant registry role here, but national cancer registries and sarcoma-specific databases (national cancer registries in Europe and North America, the Scandinavian Sarcoma Group registry, and cooperative group databases) supply nearly all outcome data for this tumour. Their consistent messages: rarity mandates pooled data, chemotherapy is associated with better survival, and late relapse is real. Where megaprostheses are used for reconstruction, national bone tumour endoprosthesis registries inform expected implant survivorship and infection rates.
Practice variation by resource setting.
- High-resource: neoadjuvant chemotherapy, navigation-assisted or patient-specific-instrument resection, particle therapy for skull base disease, custom endoprosthetic reconstruction.
- Intermediate-resource: chemotherapy with standard agents, conventional wide resection with allograft or standard modular endoprosthesis, photon radiotherapy.
- Low-resource: priority is accurate diagnosis and achieving a wide margin, accepting more ablative surgery (e.g. amputation or hindquarter resection) where reconstruction is unavailable; chemotherapy where deliverable safely. An oncologically sound amputation is superior to a marginal limb-sparing resection with no adjuvant therapy.
Controversies & Areas of Uncertainty
- Optimal chemotherapy regimen. No randomised evidence exists. Practice ranges from Ewing-type regimens (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide) to osteosarcoma-style or soft tissue sarcoma-style doxorubicin and ifosfamide combinations. Choice is centre-dependent; the argument for a Ewing-type regimen rests on the shared primitive round cell biology.
- Magnitude of chemotherapy benefit. Retrospective series are subject to selection bias — fitter, younger, localised patients receive chemotherapy. Some analyses show no significant survival gain. Most centres nonetheless offer it given the alternative is surgery alone for a high-grade sarcoma in a young patient.
- Role and timing of radiotherapy. Clearly indicated for unresectable and close-margin disease, but whether routine adjuvant radiotherapy after a genuinely wide resection reduces recurrence is unproven, and the long-term costs (growth disturbance, secondary malignancy) are substantial in adolescents.
- Particle versus photon therapy at the skull base and spine: physically attractive dose distributions, but access is limited to a small number of centres worldwide and comparative outcome data are scarce.
- Response assessment. Histological necrosis thresholds validated for osteosarcoma are not validated here; the cartilage islands do not necrose and can distort percentage estimates.
- Extraskeletal versus skeletal prognosis. Some series report better outcomes for extraskeletal disease (more often resectable with wide margins), others find no difference once margin status is controlled for.
- Targeted therapy. The HEY1-NCOA2 fusion drives Notch pathway and PTHrP-related signalling; targeting has not yet translated into clinical benefit. Enrolment in sarcoma trials and tissue banking should be offered to every patient.
CHOP UPManaging the Confirmed Case
Hook:Cut wide, drip hard, watch forever.